FDA’s Temple Pushes Feasibility, Cost-Savings Of Large, Simple Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
New tools and funding priorities support large, simple trials, now industry needs to get on board to create a more efficient, cost-effective health system, JAMA editorial says.
You may also be interested in...
Large Simple Trials Need FDA Boost, IoM Report Says
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA
FDA’s proposal to limit collection of certain safety data in late-stage and post-marketing clinical trials will only reduce the burden on sponsors, investigators and patients if drug regulators across the globe agree to the concept, pharmaceutical manufacturers say.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.